The HSF MSAB Peer-Reviewed Database

s, american academy of dermatology, 64th annual meeting, march 3–7, 2006 san francisco, CA. J Am Acad Dermatol. 2006 Mar; 54(3):AB58. IM Ig as a treatment for suppurative disease. 2005 POSTER HS treated with Dapsone Gupta.pdf Gupta S, Taibjee S, Lewis H. Hidradenitis suppurativa treated with dapsone, a case series of six patients, BRISTOL CUP POSTER. Br J Dermatol. 2005 June; 153(S1):20-51. Six cases: 3 female,1 male( treated with dapsone. Age range 31–51 years) with hidradenitis suppurativa (mean duration 9·2 years), treated with dapsone between 2002 and 2004. Dapsone 50 mg daily was commenced in all patients. One patient responded at this dose, three patients required 100 mg daily and one patient 150 mg daily. These five patients reported a significant improvement in disease activity, with a reduction in the frequency, and severity of lesions as well as symptomatic improvement.Time to response varied between 4 and 12 weeks. Treatment was well-tolerated in all patients with no significant adverse effects. All five patients continue on dapsone 50–50mg daily and are unable to reduce or stop dapsone due to relapse of their disease. The mean duration of treatment is 15·6 months (range 6–31). One patient was lost to follow-up while on dapsone 100 mg daily. 2005 Rx HS oral ciclosporin Rose.pdf Rose R, Goodfield M, Clark S. Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin. Clin Exp Dermatol Online Early. 2005; 0(0) Two cases (1 male,1 female) HS treated with oral ciclosporin. 2002 Methotrexate Limited value in Rx HS Jemec.pdf Jemec GB. Methotrexate is of limited value in the treatment of hidradenitis suppurativa. Clin Exp Dermatol. 2002; 27(6):528-529. Based on the morphological and histological similarities, as well as the possible co-occurrence of HS and CD it was therefore speculated that therapies used for CD might also be effective in HS. Three patients suffering from therapy resistant HS were treated with oral MTX in an open study. the primary lesions of the disease appeared unaffected by treatment with MTX, and the frequency of flare-ups was unchanged.